The findings suggest that use of the pacing technique during CRT should be reserved for expert operators, at least for now.
Conduction system pacing was found to be inferior to biventricular pacing for key outcomes in HFrEF with left bundle-branch ...
Medtronic announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.
Medtronic and Biotronik both took steps forward this week with their pacemaker hardware designed to target newly emerging ...
Cardiac resynchronization therapy is a key treatment for patients with HFrEF and electrical dyssynchrony, such as LBBB. While ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) ...
Medtronic snagged FDA approval for an expanded indication for its OmniaSecure defibrillation lead. Check out why this tiny ...
The European Society of Cardiology (ESC) has released a groundbreaking consensus statement on conduction system pacing (CSP), marking a significant milestone in the evolution of pacing therapy. The ...
Abbott (ABT)'s investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural ...
Late-breaking data from Abbott (ABT)'s groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results